Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) are transmitted through the same pathways. Therefore, the incidence of HBV in the HIV-infected population is higher than that in the healthy population, and is more obvious in China given the high HBV prevalence in the country. HIV and HBV co-infection can accelerate the disease process of HBV. Moreover, the incidence of cirrhosis and endstage liver disease is higher in patients co-infected with HIV and HBV than in patients infected HBV alone. When treating patients co-infected with HIV and HBV for HBV infection alone, care should be taken to avoid the induction of HIV resistance. HBV should be considered during drug selection for anti-retroviral treatment. Furthermore, the effective HBV treatment should be retained if anti-retroviral drugs require changing.
Infection with hepatitis B virus (HBV) is the main cause of chronic liver disease worldwide. HBV is transmitted t h roug h blood, se x , a nd mater na l-i n fa nt cha n nels . These transmission channels are consistent with that of the human immunodeficiency virus (HIV), and the efficiency of HBV transmission is higher than that of HI V [1] . Worldw ide, 10% of HI V-infected indiv iduals a re co -i n fec ted w it h c h ron ic H BV [2 -3] . Given t hat
China has a high incidence of hepatitis B, the incidence rate of domestic HIV patients co-infected with HBV is 14.6% [4] . Chronic HBV associated with HIV develops into cirrhosis, end-stage liver disease, or hepatocellular carcinoma faster than pure HBV infection. In addition, because most HIV patients co-infected with HBV test positive for the hepatitis B virus e antigen (HBeAg) and some test positive for HBeAg seroconversion [5] , the risk of end-stage liver disease is higher among HIV patients coinfected with HBV than that among patients infected with HBV alone [6] . Therefore, the treatment and monitoring of HIV patients co-infected with chronic HBV should receive special attention. This paper provides a review of this aspect. The incidence and mortality of AIDS, which is caused by HIV infection, have significantly decreased with the extensive application of anti-retroviral treatment (ART). ART has also significantly prolonged the average survival duration of HIV-infected individuals. However, ART is followed by increased hospitalization and fatality rates caused by non-AIDS diseases, such as liver disease caused by chronic HBV infection. Therefore, all HIV-infected indiv iduals should undergo routine screening for the presence of HBV molecular markers, such as hepatitis B virus surface antigen (HBsAg), hepatitis B virus core antibody (HBcAb), and hepatitis B virus surface antibody (HBsAb). The ultimate goal for the treatment of patients co-infected with HI V and HBV infection is the same as that for the treatment of patients infected with HBV alone: to prevent progression and to reduce the incidence and mortality of HBV-related diseases. ART should be administered when the patients exhibit HBV infection activities, with manifest with increased transaminase, ≥ 2000IU/mL HBV deoxyribonucleic acid (DNA), or endstage liver disease with hepatic fibrosis [7] . Patients with severe liver disease and cirrhosis caused by hepatitis B are required to take anti-HBV treatment.
Currently available drugs for HBV infection include inter feron, peg ylated inter feron, lamiv udine (3TC), a d e f o v i r d i p i v o x i l (A DV ), e n t e c a v i r (E T V ), a n d telbivudine (LDT). Tenofovir disoproxil fumarate (TDF) and emdtricitabine (ETC) have been approved for HIV treatment and exert therapeutic effects on HBV infection. The best treatment endpoint for HBV infection is negative HBsAg and the occurrence of HBsAb. Few HIV-infected patients, however, reach these treatment end points. More realistic treatment goals include the long-term suppression of HBV, the reduction of liver inf lammation, and the suspension or delay of liver fibrosis. For HI V patients w ith HBV infection, the f irst problem is the indication of ART. CD 4+ T lymphocyte (CD 4 cell) levels are <350/μL in individuals infected with HIV alone and < 500/μL in HIV patients with HBV co-infection. When CD 4 cell levels are <500/μL, ART should be considered as a treatment option. The current guidelines for the treatment of HI V infection in China recommend that ART should be initiated when hepatitis occurs regardless of CD 4 cell levels [8] . The specific treatment process has the following two situations.
HIV and HBV Co-Infected Patients with the Long-term Non-Progression of HIV Infection and Reluctant to Initiate ART 1) In this case, the specific medication [9] [10] is pegylated interferon. The desired therapeutic effects in patients are high level of alanine transaminase (A LT), low level of HBV-DNA, and positive HBeAg. For the treatment of cirrhosis patients co-infected w ith HI V and H BV, pegylated interferon should be avoided and telbivudine should be used alone instead. If HBV-DNA exceeds the detection limit at 24 weeks of treatment, A DV can be added to decrease the risk of drug resistance. Drug users with the early initiation of ART should be treated with a drug combination that includes TDF and LAM/ FTC.
2) Plasma H BV-DNA level is signif icantly related with the risk of hepatitis B cirrhosis and hepatocellular carcinoma. Therefore, the possibility of hepatitis activity remains in patients with high HBV-DNA level and normal ALT level. Additional measures should be taken to assess the extent of liver inf lammation. These measures include liver biopsy or non-invasive examination, such as plasma liver fibrosis markers or transient liver elastic scanning (Fibroscan). Liver biopsy scoring systems can be used as a reference for the suitability of a specific treatment. For example, scores >A2 and/or F2 in the METAVIR system indicate that anti-HBV therapy should be provided via the above-mentioned therapeutic schemes.
3) W he n u s e d t o t r e a t H I V p a t i e nt s w it h H B V infection without the initiation of ART, ETV can induce M184V mutations and then generate lamiv udine and emdtricitabine resistance. Thus, ET V cannot be used a lone for t he t reat ment of H BV pat ient s w it h H I V infection [11] .
HIV/HBV Co-Infected Patients with the Initiation of ART or in the Process of ART 1) Although HBV is not resistant to lamivudine, patients who have ever taken lamivudine should be treated with A RT that includes TDF and LA M/FTC [12] [13] to delay HBV resistance to LAM or FTC. For patients with HIV and H BV co-infection, the generation of lamiv udine resi st a nce i n H BV i s f a ster t ha n t hat i n pu re H BV infection, and is approximately 50% in 2 years and 90% in 4 years [14] . If HBV patients with HIV infection have received ART of LAM combined with TDF for 48 weeks, HBV load continues to exceed the lower limit of detection, and LAM/FTC resistance or HBV rebound is absent, then the patients can achieve effective HBV suppression under the original regimen without immediate treatment with ETV [15] .
2) I f there is H BV resistance to lamiv udine, TDF should be added or used instead of lamivudine in ART. H BV-DNA ca n not be completely suppressed by t he combination of TDF and LA M, although theoretically, the combination of TDF and ETV can be used to enhance the efficacy of anti-HBV treatment. However, this effect remains unconfirmed by clinical studies. Patients with Fanconi syndrome after TDF should receive tenofovir d i soprox i l f u ma rate combi ned w it h probenec id to decrease the rena l tox icit y associated w ith TDF [16] .
Alternatively, ETV can be added to ART, and the dosage should be adjusted from 0.5 mg per day to 1 mg per day. ETV has cross-resistance to TDF and FTC; thus, HBVi n fec ted i nd iv idua ls may become resista nt to ET V. Therefore, when these patients are treated with ETV, the level of HBV-DNA should be closely monitored (once every 3 months) to determine HBV breakthrough as soon as possible. TDF should be added or used instead of ETV in treating ETV-resistant patients. ETV can be added to the treatment of TDF-resistant patients. However, HBV is not resistant to TDF in vitro.
3) If ART is only effective against HBV because of HIV resistance, the drug with efficacy against HBV should be retained even when other drugs in ART are changed.
Medication course: Patients should receive pegylated interferon once a week for 48 weeks; nucleoside reverse t ra nsc r ipta se i n h ibitor (L DT a nd A DV) ca n not be suspended until HBsAg is negative for 6 months. LDT and A DV should be suspended under close monitoring if ART is not initiated under the following conditions: if the patient turns from HBeAg (+) to HBeAb (+) for more than 6 months or HBsAg disappears; and HBsAb (+) lasts for more than 6 months or HBsAb(+) appears after the treatment of original HBeAg (-) for more than 6 months. If the patient has initiated ART and the nucleoside reverse transcriptase inhibitors have to be replaced, anti-HBV drugs must be stopped under close monitoring to avoid the rebound effect. In addition, patients with combined infections should be treated with long-term anti-HBV therapy. The relapse rate is approximately 30 % [17] [18] when the drugs are prematurely stopped before the appropriate time. Relapse af ter dr ug w ithdrawa l may exacerbate the damage to liver function and even result in hepatic decompensation. In case of relapse, the original anti HBV treatment should be added immediately. Therapeutic effect evaluation [19] : 1) Primar y nonresponse. After 12 weeks of treatment, the amplitude of HBV-DNA load should decrease by <1log10. 2) Complete response. After 24 weeks of treatment, HBV-DNA load should be lower than the detection limit in the RT-PCR test (HBV-DNA being lower than the lower limit at 24 weeks indicates the low incidence of drug resistance [20] );
3) Partial response: HBV-DNA decreases to >1log10 at 24 weeks but remains higher than the detection limit. 4) Sustained response. During treatment, the viral load is lower than the detection limit. Six months after drug withdrawal, the viral load remains below the lower limit of detection. After 12 weeks of treatment, for patients good compliance but no primary response or whose HBV-DNA load increases by >1log10 compared with the lowest level of viral load at 12 weeks of treatment, genetic resistance tests should be carried out af ter the conf irmation of good compliance. When LAM resistance exists, FTC and LDT should be avoided and TDF can be added [12, 21] . The dosage of nucleoside antiviral drugs should be carefully adjusted for patients with renal impairment. Follow-up review: A fter the initiation of anti-HBV therapy, HBV-DNA levels should be reviewed every 12 weeks to assess the efficacy of antiviral treatment. For patients who are positive for E antigen, HBeAg levels should be reviewed every 6 months. The regular detection of H BV-DNA and the quantif ication of H Be AG and HBeAb should improve the prognosis of patients with possible HBeAG seroconversion. A LT level should be closely monitored and reviewed once a month during anti-HBV treatment. If ALT level stabilizes within 6 months, the review can be extended to once every 3 months. Given that chronic hepatitis B itself is an immune-mediated disease, immune reconstitution may be accompanied by increased transaminase levels after the initiation of anti-HI V and/or anti-HBV. The application of TDF+FTC A RT can decrease the risk for immune reconstitution associated with chronic hepatitis B [22] . After the initiation of A RT, i m mu nolog ic f u nc t ions a re reconst r uc ted, possibly leading to H BV-related hepatitis activation, wh ich ma n i fests as i ncreased CD+4 T ly mphoc y tes a nd A LT a f ter t reat ment. T herefore, l iver f u nc t ion should be closely monitored after A RT. Significantly increased A LT levels indicate jaundice and damage to liver synthetic function. Thus, a consultation with a liver specialist is needed. In addition, some ART medication may also elevate liver transaminase. The elevation of liver transaminase caused by this factor is more common in HBV associated with HIV infection [23] . This kind of damage is negligible and drug suspension and special treatment are not needed. However, when ALT increases to 5-10 times the upper limit of normal (ULN), drugs for liver treatment should be actively sought. If the patients exhibit allergic reactions (fever and rash) and hepatitis s y mptoms (nau sea , vom it i ng , abdom i na l pa i n, a nd jaundice), the suspected medications should be stopped. E lev ated l iver en z y mes i n H I V pat ient s w it h H BV infection indicate HBeAg seroconversion. Increased ALT during A RT may indicate a combination of remaining viral infection, such as hepatitis A, hepatitis C, hepatitis E, and alcoholic and non-alcoholic fatty liver diseases. Therefore, the cause of the increase in liver enzymes must be first identified before considering the suspension of the suspected drugs.
Declarations
